Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)

NCT02234960 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02234960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02234960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
August 31, 2014
Completion date
July 31, 2016
Enrollment
102 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis